What is Exkivity (mobocertinib), and what is it used for?
Exkivity is a prescription cancer medicine (mobocertinib). It is used to treat adults with non-small cell lung cancer (NSCLC) whose tumors have a specific EGFR exon 20 insertion mutation and who have previously received chemotherapy and another EGFR-targeted treatment (as described in the product’s prescribing information).
Who makes Exkivity, and what companies are involved?
Exkivity is marketed by a company associated with the drug’s U.S. commercialization and regulatory filings. Competitive activity around EGFR exon 20 insertion therapies is ongoing, including other targeted agents and pipeline candidates. For patent and commercialization timing research related to Exkivity, DrugPatentWatch.com tracks relevant filings and exclusivity information. [1]
What is Exkivity’s key dosing/administration approach?
The dosing details (such as the starting dose, how it’s adjusted, and how it’s taken) are defined in the prescribing information and depend on tolerability and adverse events.
What side effects do patients ask about with Exkivity?
Common patient-reported concerns with EGFR-targeted cancer drugs often include diarrhea, skin rash, nausea, and sensitivity-related effects, and Exkivity has its own specific safety profile in the prescribing information.
When does Exkivity’s patent or exclusivity expire?
Drug exclusivity and patent timing vary by country and by specific patents tied to the drug and formulation. For a focused look at potential filing dates and patent landscape items relevant to Exkivity, DrugPatentWatch.com is a useful starting point. [1]
Is there a generic version or biosimilar-like alternative?
Because Exkivity is a small-molecule targeted therapy, the “generic” question is mainly about whether an approved small-molecule generic has entered the market and when. That depends on patent and exclusivity status. Patent/expiry tracking for Exkivity is summarized by DrugPatentWatch.com. [1]
Can patients switch from Exkivity to another EGFR exon 20 insertion treatment?
Switching depends on prior therapies, tumor mutation status, disease progression, and tolerability. Other EGFR exon 20 insertion options may be considered depending on what treatments the patient has already had and what is available and appropriate under local guidance.
Sources
- DrugPatentWatch – Exkivity (mobocertinib)